Nigel Rawson is a pharmacoepidemiologist and pharmaceutical policy researcher based in Saskatoon, Saskatchewan. Educated in the United Kingdom, he holds an M.Sc. in statistics and a Ph.D. in pharmacoepidemiology. Dr. Rawson has performed epidemiologic studies of the use of drugs and their outcomes for over 40 years and published more than 140 book chapters and articles in peer-reviewed journals. He is also the author of the monograph “Drug Safety: Problems, Pitfalls and Solutions in Identifying and Evaluating Risk.” He held academic research positions in the United Kingdom until the end of 1989 and subsequently held professorships at the University of Saskatchewan and Memorial University of Newfoundland in Canada. His research activities focused on population-based studies of the use and safety of drugs using administrative healthcare utilization data and the evaluation of issues impacting access to new medicines.

Dr. Rawson has also been a senior researcher in an independent research centre in one of the United States’ largest health insurers, where he collaborated with the Food and Drug Administration on drug safety studies, and GlaxoSmithKline’s only epidemiologist in Canada providing advice and analysis for the company’s medicines and vaccines. Between 2012 and 2020, Dr. Rawson was President of Eastlake Research Group whose mission was to create evidence-based responses to pharmaceutical and health policy issues.